- 17.11.2026
- News
IQOS in Lausanne: How public health advocacy challenged Philip Morris's plans
An article published on 16 November in Swiss Medical Weekly revisits the opposition to Philip Morris's planned IQOS flagship store in Lausanne. The case illustrates how independent scientific research, coordinated advocacy and political action can help counter the tobacco industry's marketing strategies.
Régis Colombo/diapo.ch CC BY-NC 2.0
In 2016, Philip Morris International announced plans to open a 700 m² space in Lausanne entirely dedicated to IQOS, its heated tobacco device. Far more than a conventional store, the project included a retail area, an exhibition space, a café-restaurant and an event venue. The aim was to promote IQOS by associating it with technology, innovation and social interaction.
For tobacco prevention advocates, this strategy represented an attempt to renormalise tobacco use, particularly among young people.
A coordinated response backed by science
In response to the project, several public health organisations, medical associations and researchers mobilised. Their efforts combined political advocacy, dialogue with authorities, legal objections and the production of independent scientific evidence.
Research into IQOS emissions revealed, in particular, the presence of toxic substances characteristic of cigarette smoke. These findings challenged Philip Morris's claims that its device offered a smoke-free alternative. The company unsuccessfully attempted to have the scientific publication retracted.
In 2017, the authorities granted the building permit but prohibited the use of IQOS inside the premises, except in enclosed smoking rooms. This restriction threatened to undermine the commercial concept developed by Philip Morris.
The company eventually abandoned the project in 2018, citing commercial reasons. The following year, it opened a much smaller store in another part of Lausanne.
Lessons for tobacco prevention
Beyond this specific episode, the article's three authors, Valentine Ballmer, Karin Zürcher and Luc Lebon from Unisanté, highlight the mechanisms through which the tobacco industry seeks to circumvent public health protection measures.
The introduction of new products is regularly accompanied by marketing strategies that exploit regulatory gaps and scientific uncertainty. By presenting these products as technological innovations or less harmful alternatives, the industry also seeks to increase their social acceptability. When legislation is slow to respond, these products have already had time to establish themselves on the market and shape public perceptions.
The Lausanne experience therefore highlights the need for a sufficiently comprehensive and forward-looking regulatory framework that covers emerging tobacco and nicotine products without creating new opportunities to circumvent existing restrictions. It also underscores the crucial role of independent scientific research in assessing industry claims against available evidence and informing political decision-making.
Finally, the case demonstrates the importance of coordinated action among researchers, prevention organisations, medical associations and policymakers. Even in a legislative environment historically favourable to the tobacco industry, sustained collective action grounded in robust scientific evidence can help change practices and strengthen public health protection.
Source: Ballmer V., Zürcher K., Lebon L. (2026). IQOS “flagship store”: a case study of public health advocacy against tobacco industry marketing in Switzerland. Swiss Medical Weekly, 156:5483.